New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 11, 2012
11:25 EDTDKAM, DKAM, LTBR, LTBR, NBS, NBS, LQMT, LQMT, NVTL, NVTL, ASUR, ASUR, GALE, GALE, LLTC, LLTC, AEMD, AEMD, TAS, TAS, COPY, COPY, CDXC, CDXC, LLEN, LLEN, LPH, LPHRedChip Companies to host a conference
15th Annual Small-Cap Conference is being held in San Francisco on October 15 with webcasted company presentations to begin at 11:30 am. Webcast Link
News For LPH;LLEN;CDXC;COPY;TAS;AEMD;LLTC;GALE;ASUR;NVTL;LQMT;NBS;LTBR;DKAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 26, 2014
13:50 EDTNBSNeoStem to host a KOL event
Chairman & CEO Smith and CMO Losordo host a Key Opinion Leader Event with the Director of Cardiology at Cedars-Sinai Heart Institute, Dr. Timothy Henry, who discusses the significance of the Phase 2 PreSERVE AMI clinical trial in a meeting being held on December 1 at 4:30 pm. Webcast Link
November 24, 2014
13:15 EDTNBSNeoStem mentioned positively at Maxim
Subscribe for More Information
November 21, 2014
15:26 EDTNBSNeoStem provides info on the design of the Phase 2 PreSERVE AMI trial
Subscribe for More Information
09:17 EDTGALEOn The Fly: Pre-market Movers
Subscribe for More Information
November 20, 2014
16:22 EDTGALEGalena announces $55M purchase agreement with Lincoln Park Capital
Galena Biopharma announced the execution of a purchase agreement for up to $55M with Lincoln Park Capital Fund, a Chicago-based institutional investor. Under the terms of the purchase agreement dated November 18, LPC initially purchased $5M of Galena common stock at a price of $2.00 per share, 9% higher than the market close as of November 18, 2014. Thereafter, at its sole discretion, Galena may sell up to $50M worth of common stock to LPC over the 36-month term of the purchase agreement, subject to the conditions and limitations set forth in the purchase agreement. Under the terms of the purchase agreement, LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Galena common stock and is obligated to purchase at times and amounts controlled by the company. In consideration for entering into the agreement the company issued shares of its common stock to LPC as a commitment fee. Galena plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.
November 19, 2014
16:37 EDTLTBRLightbridge announces Q3 business update
Subscribe for More Information
07:16 EDTAEMDAethlon Medical to provide Hemopurifier for Ebola under FDA 'emergency use' path
Aethlon Medical disclosed that it will provide Hemopurifier therapy under FDA expanded access "emergency use" provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States. Aethlon previously disclosed that it would provide Hemopurifier therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment.
07:09 EDTNBSJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
09:20 EDTNBSOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTCDXCChromaDex initiated with a Buy at Sidoti
Subscribe for More Information
07:37 EDTGALEStifel to hold a conference
Subscribe for More Information
07:20 EDTNBSNeoStem volatility elevated into presenting data
Subscribe for More Information
07:09 EDTGALEGalena completes enrollment in GALE-401 Phase 2 clinical trial
Galena Biopharma announced the completion of enrollment in the GALE-401, or Anagrelide Controlled Release, Phase 2 Clinical Trial. The Phase 2, clinical proof-of-concept study is treating 18 patients with elevated platelet counts in myeloproliferative neoplasms, or MPNs, including Essential Thrombocythemia, or ET, Polycythemia Vera, or PV, and Primary Myelofibrosis, or PMF. The Phase 2 trial is an open-label, single-arm, multicenter study designed to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure plasma concentrations of anagrelide. The platelet lowering ability of GALE-401 will be measured by the proportion of patients that achieve a complete or partial platelet response for at least four weeks during 24 weeks of treatment. With enrollment complete, patients will now be followed for platelet response while they continue study treatment.
07:09 EDTNBSNeoStem to host conference call
Subscribe for More Information
November 17, 2014
18:32 EDTNBSOn The Fly: After Hours Movers
Subscribe for More Information
17:18 EDTNBSNeoStem announces initial positive data from Phase 2 PreSERVE AMI clinical trial
NeoStem announced initial positive data from its 161 patient Phase 2 PreSERVE AMI,or acute myocardial infarction, clinical trial. These data are based on all enrolled patients being treated and having received six month follow-up for imaging and twelve month median length follow up for mortality, adverse events, serious adverse events, SAEs, and major adverse cardiac events, MACE."For cardiologists, our key goal is to keep patients from progressing to worsening heart muscle function and death after a major heart attack," said Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University and Lead Principal Investigator of the PreSERVE AMI study. "It is encouraging to see clinically meaningful results this early in the study, and I look forward to future data readouts."
11:11 EDTNBSHigh option volume stocks:
Subscribe for More Information
November 14, 2014
15:34 EDTAEMDAethlon Medical device used to cure German Ebola patient, Fox reports
Subscribe for More Information
10:00 EDTNBSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Deutsche Bank... Advance Auto Parts (AAP) initiated with a Buy at Sterne Agee... AutoZone (AZO) initiated with an Underperform at Sterne Agee... Carter's (CRI) initiated with a Buy at Sterne Agee... Children's Place (PLCE) initiated with a Neutral at Sterne Agee... Container Store (TCS) initiated with a Fair Value at CRT Capital... DHT Holdings (DHT) initiated with a Buy at UBS... Diana Shipping (DSX) initiated with a Neutral at UBS... Genuine Parts (GPC) initiated with a Neutral at Sterne Agee... National Oilwell (NOV) initiated with a Neutral at UBS... Navios Acquisition (NNA) initiated with a Buy at UBS... NeoStem (NBS) assumed with a Buy at Maxim... O'Reilly Automotive (ORLY) initiated with a Neutral at Sterne Agee... Scorpio Bulkers (SALT) initiated with a Neutral at UBS... Star Bulk Carriers (SBLK) initiated with a Neutral at UBS... Teekay Tankers (TNK) initiated with a Buy at UBS... The Buckle (BKE) initiated with an Underweight at BB&T... TriMas (TRS) initiated with an Overweight at JPMorgan... TriplePoint Venture (TPVG) initiated with a Buy at UBS... Tsakos Energy (TNP) initiated with a Buy at UBS... USD Partners (USDP) initiated with an Outperform at Credit Suisse... Zumiez (ZUMZ) initiated with a Buy at BB&T.
09:07 EDTNBSNeoStem assumed with a Buy at Maxim
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use